Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Jia Fan
- Target Recruit Count
- 456
- Registration Number
- NCT04649489
- Locations
- 🇨🇳
Zhongshan hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Beijing Cancer Hospital, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, Beijing, China
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT04642365
- Locations
- 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇨🇦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇦🇺Peter Maccallum Cancer Institute; Clinical Trial Unit, Melbourne, Victoria, Australia
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT04639245
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
- Conditions
- Locally Advanced Urothelial CarcinomaLocally Advanced Urethral Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urothelial CarcinomaLocally Advanced Bladder Urothelial Carcinoma
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 3
- Registration Number
- NCT04637594
- Locations
- 🇺🇸
CHI Health Saint Francis, Grand Island, Nebraska, United States
🇺🇸CHI Health Good Samaritan, Kearney, Nebraska, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT04632992
- Locations
- 🇺🇸
Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States
🇺🇸Ascension St. John Hospital, Detroit, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 46
- Registration Number
- NCT04630730
- Locations
- 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭Klinik Hirslanden - Onkozentrum Hirslanden, Zürich, Switzerland
🇨🇭UniversitaetsSpital Zuerich, Zurich, Switzerland
Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Registration Number
- NCT04630210
Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 58
- Registration Number
- NCT04624399
- Locations
- 🇬🇧
Barts and London Hospital NHS Trust, London, United Kingdom
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT04622228
- Locations
- 🇨🇳
Cancer Hospital , Chinese Academy of Medical, Beijing City, China
🇨🇳West China Hospital - Sichuan University, Chengdu City, China
🇨🇳Second Affiliated Hospital of Third Military Medical University, Chongqing, China
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT04619797
- Locations
- 🇧🇪
Vitaz, Sint Niklaas, Belgium
🇫🇷CHU Strasbourg - Nouvel Hopital Civil, Strasbourg, France
🇯🇵The Cancer Institute Hospital of JFCR, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.